Search Result

Results for "

2C19

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Autophagy (10) Bacterial (8) Biochemical Assay Reagents (1) Calcium Channel (1) Cannabinoid Receptor (1) Cytochrome P450 (40) DNA/RNA Synthesis (1) Drug Metabolite (4) FGFR (1) Fluorescent Dye (1) Fungal (1) Histamine Receptor (6) HIV (2) Influenza Virus (1) Isotope-Labeled Compounds (6) JAK (1) NAMPT (1) Notch (1) P2Y Receptor (3) Parasite (3) Phospholipase (4) PPAR (8) Proton Pump (6) Reverse Transcriptase (1) Small Interfering RNA (siRNA) (1) Virus Protease (2) γ-secretase (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (10) Endocrinology (3) Infection (18) Inflammation/Immunology (4) Metabolic Disease (15) Neurological Disease (13)

By Targets:

5-HT Receptor (1)

Autophagy (10)

Bacterial (8)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Cannabinoid Receptor (1)

Cytochrome P450 (40)

DNA/RNA Synthesis (1)

Drug Metabolite (4)

FGFR (1)

Fluorescent Dye (1)

Fungal (1)

Histamine Receptor (6)

HIV (2)

Influenza Virus (1)

Isotope-Labeled Compounds (6)

JAK (1)

NAMPT (1)

Notch (1)

P2Y Receptor (3)

Parasite (3)

Phospholipase (4)

PPAR (8)

Proton Pump (6)

Reverse Transcriptase (1)

Small Interfering RNA (siRNA) (1)

Virus Protease (2)

γ-secretase (1)

By Research Areas:

Cancer (20)

Cardiovascular Disease (10)

Endocrinology (3)

Infection (18)

Inflammation/Immunology (4)

Metabolic Disease (15)

Neurological Disease (13)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113739

Desmethylcitalopram hydrochloride DCIT hydrochloride	Cytochrome P450	Neurological Disease
Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-B0725S

Doxepin D3 Hydrochloride	Histamine Receptor Cytochrome P450	Neurological Disease
Doxepin-d₃ (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2[1][2].

HY-B0258

Gemfibrozil 1 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-148822

Nampt activator-2	NAMPT	Neurological Disease
Nampt activator-2 (compound 34) is a potent NAMPT activator, with EC₅₀ of 0.023 μM. Nampt activator-2 shows moderate activity against CYP2C9 (0.060 μM), 2D6 (0.41 μM) and 2C19 (0.59 μM) .

HY-113739S1

Desmethylcitalopram-d4 hydrochloride DCIT-d₄ hydrochloride	Cytochrome P450 Isotope-Labeled Compounds	Neurological Disease
Desmethylcitalopram-d₄ hydrochloride is deuterated labeled Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258R

Gemfibrozil (Standard) 1 Publications Verification CI-719 (Standard)	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-117026

LKY-047	Cytochrome P450	Metabolic Disease Inflammation/Immunology
LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC₅₀ of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A .

HY-B0725

Doxepin Hydrochloride 4 Publications Verification	Histamine Receptor Cytochrome P450	Neurological Disease Cancer
Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant . . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system . . Doxepin has also been proposed as a protective factor against oxidative stress . .

HY-151254

CYP2C19-IN-1	Cytochrome P450 Influenza Virus DNA/RNA Synthesis	Infection
CYP2C19-IN-1 (compound 20d) is a potent *CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a K_i value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-148907

CS640	Biochemical Assay Reagents	Cancer
CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC₅₀ values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC₅₀ values of 6 and 10 μM, respectively .

HY-B0725R

Doxepin Hydrochloride (Standard)	Histamine Receptor Cytochrome P450	Neurological Disease Cancer
Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant . . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system . . Doxepin has also been proposed as a protective factor against oxidative stress . .

HY-151251

CYP2C9/CYP2C19-IN-1	Cytochrome P450 Virus Protease	Infection
CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-151253

CYP2C1/CYP2C19-IN-2	Cytochrome P450 Virus Protease	Infection
CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .

HY-RS03458

CYP2C19 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP2C19 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP2C19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP2C19 Human Pre-designed siRNA Set A CYP2C19 Human Pre-designed siRNA Set A

HY-B1184

Mephenytoin

1 Publications Verification

Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
HY-W008772

4-Hydroxymephenytoin

Drug Metabolite Others

4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate.
HY-B1184S1

Mephenytoin-d5

Cytochrome P450 Neurological Disease

Mephenytoin-d₅ is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1].
HY-B2015

Carbosulfan

Cytochrome P450 Parasite Infection

Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers).
HY-B1184S2

Mephenytoin-d8

Cytochrome P450 Neurological Disease

Mephenytoin-d₈ is the deuterium labeled Mephenytoin[1]. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[2].

Mephenytoin 1 Publications Verification
Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .

4-Hydroxymephenytoin	Drug Metabolite	Others
4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate.

Mephenytoin-d5	Cytochrome P450	Neurological Disease
Mephenytoin-d₅ is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1].

Carbosulfan	Cytochrome P450 Parasite	Infection
Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers).

Mephenytoin-d8	Cytochrome P450	Neurological Disease
Mephenytoin-d₈ is the deuterium labeled Mephenytoin[1]. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[2].

HY-W008772S

4-Hydroxymephenytoin-d3	Drug Metabolite	Others
4-Hydroxymephenytoin-d₃ is the deuterium labeled 4-Hydroxymephenytoin. 4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate[1][2].

HY-B1184A

(S)-Mephenytoin (+)-Mephenytoin	Cytochrome P450	Neurological Disease
(S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism .

HY-118283

5-Hydroxylansoprazole 1 Publications Verification AG1908	Proton Pump	Metabolic Disease
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases .

HY-B0281A

Ranitidine hydrochloride 1 Publications Verification	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology
Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of *CYP2C19* and CYP2C9 .

HY-B0693

Ranitidine	Histamine Receptor Bacterial Cytochrome P450	Infection Metabolic Disease Endocrinology Cancer
Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine is a weak inhibitor of *CYP2C19* and CYP2C9 .

HY-103392

Stiripentol 3 Publications Verification BCX2600	Cytochrome P450	Neurological Disease
Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with K_i of 1.59±0.07 and 0.516±0.065 μM and IC₅₀ of 1.58 and 3.29 μM, respectively.

HY-B2015S

Carbosulfan-d18	Cytochrome P450 Parasite	Infection
Carbosulfan-d₁₈ is the deuterium labeled Carbosulfan. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.

HY-135111

4-Desmethoxy Omeprazole	Drug Metabolite	Infection Metabolic Disease Cancer
4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .

HY-B0113S

Omeprazole-d₃ H 16868-d₃	Proton Pump Bacterial Autophagy	Infection Metabolic Disease Cancer
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-B0281AS

Ranitidine-d6 hydrochloride	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-N6023

Thermopsoside	Cytochrome P450	Others
Thermopsoside is a flavone derivative isolated from Aspalathus linearis. Thermopsoside exhibits inhibitory effects on CYP450 isozymes with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM, 32.0 μM, for CYP3A4, CYP2C19, CYP2D6 and CYP2C9, respectively .

HY-137258

(±)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with K_i values of 0.25 and 5.3 μM for *CYP2C19*, respectively .

HY-103392S

Stiripentol-d9	Isotope-Labeled Compounds Cytochrome P450	Neurological Disease
Stiripentol-d₉ is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively[1][2].

HY-B0113

Omeprazole 2 Publications Verification H 16868	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-W008364

Olivetol	Cytochrome P450 Cannabinoid Receptor	Neurological Disease
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits *CYP2C19* and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-B0113A

Omeprazole sodium 2 Publications Verification H 16868 sodium
Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-17356

Fenofibrate 10+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for *CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-50845

Avagacestat 2 Publications Verification BMS-708163	γ-secretase Notch	Cancer
Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC₅₀s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC₅₀ of 0.84 nM and shows weak inhibition of CYP2C19, with IC₅₀ of 20 μM. Avagacestat can be used for Alzheimer disease research.

HY-W011235

Norfluoxetine hydrochloride	5-HT Receptor Calcium Channel Drug Metabolite	Neurological Disease
Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 18 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and *CYP2C19* with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-100386

Ticlopidine PCR 5332
Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.

HY-B0113S1

Omeprazole-d3-1 H 16868-d₃-1	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-147807

HIV-1 inhibitor-40	HIV Cytochrome P450	Infection
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC₅₀ of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC₅₀ values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-17356R

Fenofibrate (Standard) 10+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for *CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-N6948S

Linalyl acetate-d6	Isotope-Labeled Compounds	Inflammation/Immunology
Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S4

Omeprazole-d3 sodium H 16868-d₃ sodium	Autophagy Phospholipase Proton Pump Bacterial Isotope-Labeled Compounds	Infection Metabolic Disease Cancer
Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S3

Omeprazole-13CD3 H 16868-¹³C,d₃	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-116862

Dibenzylfluorescein DBF	Cytochrome P450 Fluorescent Dye	Others
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W008772

4-Hydroxymephenytoin	Structural Classification Monophenols Classification of Application Fields Source classification Other Diseases Phenols Endogenous metabolite Disease Research Fields	Drug Metabolite
4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate.

HY-W008364

Olivetol	Structural Classification other families Microorganisms Source classification Phenols Polyphenols Plants	Cytochrome P450 Cannabinoid Receptor
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits *CYP2C19* and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-N2071

Cedrol 1 Publications Verification (+)-Cedrol; α-Cedrol	Cedrus deodara (Roxburgh) G. Don Classification of Application Fields Pinaceae Terpenoids Sesquiterpenes Source classification Plants Inflammation/Immunology Disease Research Fields Cancer	Cytochrome P450 Fungal
Cedrol is a bioactive sesquiterpene, a potent competitive inhibitor of cytochrome P-450 (CYP) enzymes. Cedrol inhibits CYP2B6-mediated bupropion hydroxylase and CYP3A4-mediated midazolam hydroxylation with K_i of 0.9 μM and 3.4 μM, respectively. Cedrol also has weak inhibitory effect on CYP2C8, CYP2C9, and CYP2C19 enzymes . Cedrol is found in cedar essential oil and poetesses anti-septic, anti-inflammatory, anti-spasmodic, tonic, astringent, diuretic, insecticidal, and anti-fungal activities .

HY-N6023

Thermopsoside	Flavonoids Classification of Application Fields Flavones Astragalus microcephalus Willd. Source classification Other Diseases Phenols Polyphenols Plants Compositae Disease Research Fields	Cytochrome P450
Thermopsoside is a flavone derivative isolated from Aspalathus linearis. Thermopsoside exhibits inhibitory effects on CYP450 isozymes with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM, 32.0 μM, for CYP3A4, CYP2C19, CYP2D6 and CYP2C9, respectively .

Cat. No.	Product Name	Chemical Structure

HY-B0725S

Doxepin D3 Hydrochloride
Doxepin-d₃ (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2[1][2].

HY-113739S1

Desmethylcitalopram-d4 hydrochloride
Desmethylcitalopram-d₄ hydrochloride is deuterated labeled Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B1184S1

Mephenytoin-d5

Mephenytoin-d₅ is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1].
HY-B1184S2

Mephenytoin-d8

Mephenytoin-d₈ is the deuterium labeled Mephenytoin[1]. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[2].

HY-W008772S

4-Hydroxymephenytoin-d3
4-Hydroxymephenytoin-d₃ is the deuterium labeled 4-Hydroxymephenytoin. 4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate[1][2].

HY-B2015S

Carbosulfan-d18
Carbosulfan-d₁₈ is the deuterium labeled Carbosulfan. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.

HY-B0113S

Omeprazole-d₃
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-B0281AS

Ranitidine-d6 hydrochloride
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-103392S

Stiripentol-d9
Stiripentol-d₉ is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively[1][2].

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-N6948S

Linalyl acetate-d6

Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S3

Omeprazole-13CD3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-100386S

Ticlopidine-d4

Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively[1]. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively[2][3].

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks